Biotech Values

[dewophile]

Nltx

The company has been talking about an IL-2 inhibitor that they will disclose this year. Here it is. An interesting feature is the resistance to low PH and protease degradation which may make it suitable for oral administration

https://acrabstracts.org/abstract/development-of-a-computationally-designed-hyperstable-dual-inhibitor-of-the-il-2-and-il-15-receptors-a-novel-therapeutic-candidate-for-inflammatory-conditions/